JP2007533740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533740A5 JP2007533740A5 JP2007509507A JP2007509507A JP2007533740A5 JP 2007533740 A5 JP2007533740 A5 JP 2007533740A5 JP 2007509507 A JP2007509507 A JP 2007509507A JP 2007509507 A JP2007509507 A JP 2007509507A JP 2007533740 A5 JP2007533740 A5 JP 2007533740A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- hydrogen
- cycloalkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 56
- 239000001257 hydrogen Chemical group 0.000 claims 56
- -1 Tetrahydropyridin-2-yl moiety Chemical group 0.000 claims 52
- 125000001153 fluoro group Chemical group F* 0.000 claims 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000002431 hydrogen Chemical group 0.000 claims 25
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000004305 biphenyl Chemical group 0.000 claims 3
- 235000010290 biphenyl Nutrition 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 101800001718 Amyloid-beta protein Proteins 0.000 claims 1
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 CC1NCCC(*)CC(*)(*)*1* Chemical compound CC1NCCC(*)CC(*)(*)*1* 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56453804P | 2004-04-22 | 2004-04-22 | |
| PCT/US2005/012189 WO2005108391A1 (en) | 2004-04-22 | 2005-04-08 | Amides as bace inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533740A JP2007533740A (ja) | 2007-11-22 |
| JP2007533740A5 true JP2007533740A5 (enExample) | 2008-04-17 |
Family
ID=34966238
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509507A Pending JP2007533740A (ja) | 2004-04-22 | 2005-04-08 | Ｂａｃｅ阻害剤としてのアミド |
| JP2007509508A Ceased JP2007533741A (ja) | 2004-04-22 | 2005-04-08 | Ｂａｃｅ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509508A Ceased JP2007533741A (ja) | 2004-04-22 | 2005-04-08 | Ｂａｃｅ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7618978B2 (enExample) |
| EP (2) | EP1740575A2 (enExample) |
| JP (2) | JP2007533740A (enExample) |
| WO (2) | WO2005108358A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534950A1 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US20050239790A1 (en) * | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US20060014737A1 (en) * | 2004-03-09 | 2006-01-19 | Varghese John | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors |
| CA2558034A1 (en) * | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| US7618978B2 (en) | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
| CA2572775A1 (en) * | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
| EP1773756A2 (en) | 2004-07-09 | 2007-04-18 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| JP2008507538A (ja) * | 2004-07-22 | 2008-03-13 | シェーリング コーポレイション | 置換アミドβセクレターゼインヒビター |
| CA2576782A1 (en) * | 2004-08-27 | 2006-03-09 | Elan Pharmaceuticals, Inc. | Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors |
| US20060074098A1 (en) * | 2004-08-27 | 2006-04-06 | Roy Hom | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors |
| PE20060692A1 (es) | 2004-09-21 | 2006-07-19 | Lilly Co Eli | Inhibidores bace |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| WO2007047305A1 (en) * | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| CA2624904A1 (en) * | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors |
| PT2404919E (pt) | 2005-11-08 | 2013-10-22 | Vertex Pharma | Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp |
| WO2007058862A2 (en) * | 2005-11-16 | 2007-05-24 | Merck & Co., Inc. | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2653650A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| WO2008016643A2 (en) * | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US7919511B2 (en) | 2006-08-01 | 2011-04-05 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7932270B2 (en) | 2006-08-01 | 2011-04-26 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7939534B2 (en) | 2006-08-01 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7939548B2 (en) | 2006-08-02 | 2011-05-10 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
| EP2164840A2 (en) | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| CN101868457B (zh) | 2007-09-24 | 2013-02-13 | 科门蒂斯公司 | 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物 |
| HUE049642T2 (hu) | 2007-12-07 | 2020-09-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái |
| CA2989620C (en) * | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
| WO2009106599A2 (en) * | 2008-02-29 | 2009-09-03 | Novartis Ag | Substituted piperidines as therapeutic compounds |
| EP2346500B1 (en) | 2008-10-16 | 2017-05-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2411000A4 (en) * | 2009-03-25 | 2012-09-19 | Comentis Inc | PYRROLIDIN COMPOUNDS FOR INHIBITING THE BETA-SECRETASE EFFECT AND METHOD FOR THE APPLICATION THEREOF |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| AR081587A1 (es) | 2010-06-09 | 2012-10-03 | Janssen Pharmaceutica Nv | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) |
| EA201291366A1 (ru) * | 2010-06-09 | 2013-04-30 | Янссен Фармацевтика Нв | Производные 5-амино-3,6-дигидро-1h-пиразин-2-она в качестве ингибиторов бета-секретазы (bace) |
| ES2648143T3 (es) | 2010-12-22 | 2017-12-28 | Janssen Pharmaceutica Nv | Derivados de 5,6-dihidro-imidazo[1,2-a]pirazin-8-ilamina útiles como inhibidores de la beta-secretasa (BACE) |
| US9346811B2 (en) | 2011-03-01 | 2016-05-24 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| JP5853035B2 (ja) | 2011-03-09 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な３，４−ジヒドロ−ピロロ［１，２−ａ］ピラジン−１−イルアミン誘導体 |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP3653609B1 (en) | 2013-02-12 | 2024-04-03 | Buck Institute for Research on Aging | Hydantoins that modulate bace-mediated app processing |
| US9120795B2 (en) | 2013-03-14 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | Crystalline form of a β-lactamase inhibitor |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| KR102243134B1 (ko) | 2013-06-12 | 2021-04-22 | 얀센 파마슈티카 엔.브이. | 베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체 |
| EP3008067B1 (en) | 2013-06-12 | 2017-03-29 | Janssen Pharmaceutica N.V. | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace) |
| BR112015030597A2 (pt) | 2013-06-12 | 2017-07-25 | Janssen Pharmaceutica Nv | derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace) |
| US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| CA2930199C (en) | 2013-11-12 | 2022-10-25 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases |
| HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
| JP2017538753A (ja) | 2014-12-18 | 2017-12-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ２，３，４，５−テトラヒドロピリジン−６−アミンおよび３，４−ジヒドロ−２Ｈ−ピロール−５−アミンの化合物のβセクレターゼ阻害剤 |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| PY1974248A (es) | 2018-09-13 | 2020-08-21 | Syngenta Participations Ag | Compuestos de azol-amida pesticidamente activos |
| CN109096117B (zh) * | 2018-09-25 | 2020-12-25 | 南京信息工程大学 | 1-苯基-2-硝基乙醇及其衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI902006A7 (fi) | 1987-10-21 | 1990-04-20 | Upjohn Co | Menetelmä renniini-inhibiittoreiden valmistamiseksi, jotka sisältävät 1-amino-2-hydroksi-2-heterosyklisen etyylitähteen |
| GB9812189D0 (en) | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
| FR2787782B1 (fr) | 1998-12-23 | 2001-03-16 | Omnium Traitement Valorisa | Procede de traitement d'un effluent mettant en oeuvre une nitrification/denitrification simultanees dans un biofiltre |
| AU7757400A (en) | 1999-08-09 | 2001-03-05 | Vanderbilt University | Antiviral therapy use of p-glycoprotein modulators |
| US6673821B2 (en) * | 2001-10-22 | 2004-01-06 | Enanta Pharmaceuticals, Inc. | Nitrogen heterocycle inhibitors of aspartyl protease |
| AR039555A1 (es) | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
| US7262208B2 (en) | 2002-04-30 | 2007-08-28 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of Alzheimer's disease |
| UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| DE60329316D1 (de) * | 2002-11-12 | 2009-10-29 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
| CN1863770B (zh) | 2003-08-08 | 2011-05-25 | 先灵公司 | 具有杂环取代基的环胺base-1抑制剂 |
| CA2534950A1 (en) * | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| US7618978B2 (en) | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| PE20060692A1 (es) | 2004-09-21 | 2006-07-19 | Lilly Co Eli | Inhibidores bace |
-
2005
- 2005-04-08 US US10/599,125 patent/US7618978B2/en not_active Expired - Fee Related
- 2005-04-08 JP JP2007509507A patent/JP2007533740A/ja active Pending
- 2005-04-08 EP EP05778064A patent/EP1740575A2/en not_active Withdrawn
- 2005-04-08 WO PCT/US2005/012191 patent/WO2005108358A2/en not_active Ceased
- 2005-04-08 WO PCT/US2005/012189 patent/WO2005108391A1/en not_active Ceased
- 2005-04-08 JP JP2007509508A patent/JP2007533741A/ja not_active Ceased
- 2005-04-08 EP EP05736358A patent/EP1740573A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2607514A (en) | Functionalized peptides as antiviral agents | |
| JP2010527373A5 (enExample) | ||
| JP2005539088A5 (enExample) | ||
| ATE547417T1 (de) | Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten | |
| TW200519091A (en) | Dihydropyridine compounds for treating or preventing metabolic disorders | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2006527776A5 (enExample) | ||
| JP2011511840A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| WO2006046039A3 (en) | Tetracyclic indole derivatives as antiviral agents | |
| ES2606043T3 (es) | Derivados de biarilo como moduladores de nAChR | |
| JP2007517846A5 (enExample) | ||
| JP2009526761A5 (enExample) | ||
| EP1489077A4 (en) | 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | |
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2012526838A5 (enExample) | ||
| EA200970582A1 (ru) | ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH | |
| TW200305425A (en) | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient | |
| AR056155A1 (es) | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica | |
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| US8501793B2 (en) | Blood flow promoters for cauda equina tissues | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2007504235A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| NO20091254L (no) | Terapeutiske sammensetninger |